Evidence map›Paper›PMID 32405623›Full record

ArticleEClinicalMedicine2020

Efficacy and safety of ascending dosages of albendazole against

Chandni Patel, Jean T Coulibaly, Jessica D Schulz, Yves N'Gbesso, Jan Hattendorf, Jennifer Keiser

Open access · goldAbstract read
In one paragraph

Article in EClinicalMedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Chandni PatelSwiss Tropical and Public Health Institute, Basel, Switzerland.
Jean T CoulibalySwiss Tropical and Public Health Institute, Basel, Switzerland.
Jessica D SchulzSwiss Tropical and Public Health Institute, Basel, Switzerland.
Yves N'GbessoDepartment de Agboville, Centre de Santé Urbain d'Azaguié, Côte d'Ivoire.
Jan HattendorfSwiss Tropical and Public Health Institute, Basel, Switzerland.
Jennifer KeiserSwiss Tropical and Public Health Institute, Basel, Switzerland.
University of Basel · CHSwiss Tropical and Public Health Institute · CHUniversité Félix Houphouët-Boigny · CI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe efficacy of the widely used albendazole against the soil-transmitted helminth

methodsA randomized-controlled trial was conducted in Côte d'Ivoire with preschool-aged children (PSAC), school-aged children (SAC), and adults infected with

findings111 PSAC, 180 SAC, and 42 adults were randomized and 86, 172, and 35 provided follow-up stool samples, respectively. The highest observed CR among PSAC was 27·8% (95% CI: 9·7%-53·5%) in the 600 mg albendazole treatment arm. The most efficacious arm for SAC was 600 mg of albendazole showing a CR of 25·6% (95% CI: 13·5%-41·2%), and for adults it was 400 mg of albendazole with a CR of 55·6% (95% CI: 21·2%-86·3%). CRs and ERRs did not differ significantly among treatment arms and flat dose-responses were observed. 17·9% and 0·4% of participants reported any adverse event at 3 and 24 h follow-up, respectively.

interpretationAlbendazole shows low efficacy against

fundingBill and Melinda Gates Foundation.

Indexed as

AlbendazoleDose-findingSoil-transmitted helminthsTrichuis trichiura

Identifiers

PMID32405623
PMCPMC7210508
OpenAlexW3023984861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.